Brentuximab vedotin is an anti-CD30 chimeric monoclonal antibody conjugated with the tubulin inhibitor MMAE via a protease-sensitive linker that has shown high responsiveness and manageable toxicity in the treatment of CD30+ lymphoproliferative disorders [162]. The gene discussed is TNFRSF8; the disease is lymphoproliferative syndrome.